RT Journal Article
SR Electronic
T1 Efficacy of Combined Pembrolizumab and Pelvic Radiotherapy for Bladder Cancer With Rectal Metastases
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 912
OP 915
DO 10.21873/invivo.13162
VO 37
IS 2
A1 CHIKA NAGAHISA
A1 JUNPEI IIZUKA
A1 YUKI KOBARI
A1 RYO MINODA
A1 HIRONORI FUKUDA
A1 KAZUHIKO YOSHIDA
A1 HISASHI OKUDA
A1 HIDEKI ISHIDA
A1 YOJI NAGASHIMA
A1 TOSHIO TAKAGI
YR 2023
UL http://iv.iiarjournals.org/content/37/2/912.abstract
AB Background/Aim: Rectal metastases from urothelial carcinoma (UC) are extremely rare with poor prognosis when treated with gemcitabine and cisplatin (GC) chemotherapy, radiation therapy, and total pelvic exenteration. Long-term survival has not been observed in patients treated with GC chemotherapy, radiation therapy, or total pelvic resection. However, there have been no reports on the efficacy of pembrolizumab therapy for this specific condition. Herein, we describe a case of rectal metastasis from UC, treated with combined pembrolizumab and pelvic radiotherapy. Case Report: A 67-year-old male patient with an invasive bladder tumour underwent robot-assisted radical cystectomy and ileal conduit diversion followed by neoadjuvant GC chemotherapy. The pathological findings showed high-grade UC, pT4a, with a negative surgical margin. He presented with an impacted ileus due to severe rectal stenosis on postoperative day 35 and underwent a colostomy. Pathologically, rectal biopsy confirmed rectal metastasis; thus, the patient was started on pembrolizumab 200 mg every 3 weeks and pelvic radiotherapy with a total dose of 45 Gy. The rectal metastases remained well controlled with stable disease status, and no adverse events were observed 10 months after the initiation of combined pembrolizumab and pelvic radiotherapy. Conclusion: Pembrolizumab combined with radiation therapy may be an alternative treatment for rectal metastases from UC.